‫وتكون‬ ‫املناعية‬ ‫الكفاءة‬ ‫ذوي‬ ‫أطفال‬ ‫ال‬ ‫يف‬ ‫الجتياحية‬ ‫الر�سا�سيات‬ ‫من‬ ‫للغاية‬ ‫نادر‬ ‫مظهر‬ ‫الدماغي‬ ‫القحف‬ ‫داخل‬ ‫الر�سا�سيات‬
The patient was discharged on oral voriconazole (6 mg/kg every 12 hours). At a six-week follow-up appointment, the patient underwent CT and MRI scans of the brain which showed a progression of the dense solid marginal tissue abnormality. The enhancement was consistent with a granulomatous tissue abnormality [ Figure 2A] . A residual or persistent fungal brain lesion was suspected and the patient subsequently underwent surgical exploration with further resection of the lesion. The histopathology remained consistent with that of the first resected brain lesion; however, cultures showed A. flavus growth. Oral administration of voriconazole was substituted for intravenous administration (6 mg/kg every 12 hours). Two days later, a postoperative CT scan showed a slight nonspecific enhancement in the periphery of the resected area. The patient was discharged with a prescription for oral voriconazole (6 mg/kg every 12 hours).
This report describes an invasive Aspergillus-induced brain abscess in an immunocompetent patient with no history of trauma.
Case Report
A previously healthy 12-year-old male child was referred to the King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia, in May 2010 after a sudden-onset headache and loss of consciousness for 15 minutes. He had no convulsions, abnormal movements, eye abnormalities, vision impairment, fever, vomiting or skin rashes. In addition, he had no history of trauma. On examination, the patient was stable and interactive with no obvious neurological deficits. Computed tomography (CT) of the brain showed a right occipital space-occupying lesion, suspected to be a tumour. The nasal sinuses were clear. In the current case, the patient had invasive CNS aspergillosis without paranasal sinus involvement and with no identifiable immune defects. Although he had negative Aspergillus serum galactomannan antigens, this negative result does not exclude a diagnosis of invasive aspergillosis. 13 Culture supernatants of A. flavus have demonstrated lower reactivity, with lower galactomannan concentrations.
14 Negative results could be due to factors related to the host, the assay or the fungus itself. One of the blood investigations which can be used to detect Aspergillus is the enzyme-linked immunosorbent assay Platelia ™ Aspergillus EIA (Bio-Rad Laboratories, California, USA); this assay is most favourable in patients with haematological malignancies, especially those who have undergone a haematopoietic stem cell transplant and are neutropaenic. 15 It is not clear how the patient in the present case developed the brain abscess. Although no immune defects were identified, he may nevertheless have been suffering from a rare form of immunodeficiency, such as an interleukin (IL)-4 or IL-6 deficiency; suppression of monocytes and T helper cells and interferon-gamma (IFN-γ) responses can lead to severe Aspergillus infections. 13, 16 A previous case report has indicated the beneficial role of IFN-γ treatment in combination with antifungal drugs in managing a patient with an A. fumigatus-induced brain abscess. 17 
Conclusion
Persistent cerebral Aspergillus-induced abscesses in immunocompetent patients are extremely rare and the clinical and radiological features of these cases may be similar to primary or secondary neoplasms or other forms of infection. Health professionals should therefore be aware of the symptoms of Aspergillusinduced brain abscesses, as early detection and appropriate treatment is necessary to ensure positive patient outcomes.
A one-month follow-up MRI scan of the patient showed resolution of the solid enhancing parenchymal abnormality [ Figure 2B ]. Subsequent MRI scans were performed at regular intervals, including four, six, 18 and 24 months after the second resection. After eight months of oral voriconazole treatment, (1,3) -beta-D-glucan levels were undetectable. Repeated assays for Aspergillus galactomannan also revealed undetectable levels. Antifungal treatment was discontinued after two years as there was on-going evidence of the complete resolution of the brain lesion by May 2013.
Discussion
In general, CNS aspergillosis-particularly invasive aspergillosis-is rarely observed in immunocompetent patients. 2 The brain is remarkably resistant to fungal infections due to its abundant blood supply and the relatively impermeable blood-brain barrier. Nevertheless, despite the existence of anatomical and functional barriers which protect the brain and subarachnoid space, fungal pathogens can breach these barriers under certain conditions.
2 Persistent cerebral Aspergillus abscesses in immunocompetent patients may exhibit clinical and radiological features similar to primary or secondary neoplasms or other forms of infection. 10 Only a few cases of invasive Aspergillus brain abscesses have been reported; of these, most involved adult rather than paediatric patients. 11 The management of cerebral fungal abscesses remains controversial. Antifungal therapy alone reportedly has a poor outcome for patients with CNS aspergillosis, with a high mortality rate of >90%; this is likely due to the poor penetration of the CNS by the antifungal drugs. 2 Other research has indicated that surgical resection of focal CNS aspergillosis lesions reduces the mortality rate from 64% to 39%. 2 Overall, voriconazole seems to be the drug of choice for the treatment of aspergillosis. 2 In the current case, the patient showed clinical and radiological improvement with intravenous voriconazole administration and surgical resection. However, imaging scans at a six-week follow-up revealed that the lesion had progressed despite the continued administration of oral voriconazole; this is unusual due to the high bioavailability level (82.6%) of oral voriconazole. 12 This uncommon occurrence may have been due to poor medication compliance on the part of the patient or incomplete resection which resulted in the slow progression of the remnant lesion. Unfortunately, no facilities were available to monitor the patient's exact voriconazole drug levels.
